Ernest Marshall

2.0k total citations
42 papers, 938 citations indexed

About

Ernest Marshall is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ernest Marshall has authored 42 papers receiving a total of 938 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Ernest Marshall's work include Ocular Oncology and Treatments (9 papers), Immunotherapy and Immune Responses (5 papers) and Cutaneous Melanoma Detection and Management (5 papers). Ernest Marshall is often cited by papers focused on Ocular Oncology and Treatments (9 papers), Immunotherapy and Immune Responses (5 papers) and Cutaneous Melanoma Detection and Management (5 papers). Ernest Marshall collaborates with scholars based in United Kingdom, United States and Germany. Ernest Marshall's co-authors include Michael Wolf, Emily Crawford, Mario A. Eisenberger, B. I. Lord, Allison Hall, Sheow Lei Lim, Helen Innes, P A O'Neill, Serge Leyvraz and Chinnamani Eswar and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Ernest Marshall

40 papers receiving 898 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ernest Marshall United Kingdom	17	482	287	232	221	209	42	938
Francesco De Rosa Italy	18	694 1.4×	291 1.0×	168 0.7×	98 0.4×	392 1.9×	58	1.1k
S S Legha United States	15	635 1.3×	388 1.4×	62 0.3×	129 0.6×	308 1.5×	25	974
Lorenza Di Guardo Italy	15	987 2.0×	360 1.3×	248 1.1×	118 0.5×	398 1.9×	48	1.2k
Tatsuo Teramoto Japan	17	888 1.8×	329 1.1×	372 1.6×	48 0.2×	83 0.4×	82	1.5k
Rachel N. Grisham United States	23	669 1.4×	596 2.1×	236 1.0×	71 0.3×	132 0.6×	119	1.7k
Suthee Rapisuwon United States	11	683 1.4×	329 1.1×	158 0.7×	31 0.1×	246 1.2×	30	997
Anette Weber Germany	14	490 1.0×	370 1.3×	87 0.4×	68 0.3×	77 0.4×	18	882
H Kantarjian United States	16	310 0.6×	310 1.1×	103 0.4×	69 0.3×	137 0.7×	28	1.2k
Dariusz Wołowiec Poland	20	661 1.4×	401 1.4×	95 0.4×	25 0.1×	621 3.0×	81	1.4k
Steven Blotner United States	17	598 1.2×	257 0.9×	223 1.0×	25 0.1×	31 0.1×	36	1.1k

Countries citing papers authored by Ernest Marshall

Since Specialization

Citations

This map shows the geographic impact of Ernest Marshall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernest Marshall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernest Marshall more than expected).

Fields of papers citing papers by Ernest Marshall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernest Marshall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernest Marshall. The network helps show where Ernest Marshall may publish in the future.

Co-authorship network of co-authors of Ernest Marshall

This figure shows the co-authorship network connecting the top 25 collaborators of Ernest Marshall. A scholar is included among the top collaborators of Ernest Marshall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernest Marshall. Ernest Marshall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marshall, Ernest, et al.. (2025). NSAID-mediated cyclooxygenase inhibition disrupts ectodermal derivative formation in axolotl embryos. Differentiation. 143. 100856–100856.

Schadendorf, Dirk, Lisa Zimmer, Sarah Danson, et al.. (2018). Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology. 30(2). 317–324. 15 indexed citations

Kivelä, Tero, Sophie Piperno‐Neumann, Laurence Desjardins, et al.. (2016). Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group. American Journal of Ophthalmology. 168. 217–226. 27 indexed citations

Leyvraz, Serge, Sophie Piperno‐Neumann, Stefan Suciu, et al.. (2014). Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Annals of Oncology. 25(3). 742–746. 92 indexed citations

O’Brien, Mary, Paul Lorigan, Lionel Bosquée, et al.. (2011). Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062. European Journal of Cancer. 47(15). 2322–2330. 21 indexed citations

Weber, Jeffrey S., Bruce G. Redman, Uwe Trefzer, et al.. (2009). Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer. 115(17). 3944–3954. 63 indexed citations

Marshall, Ernest, et al.. (2008). Chemotherapy induced febrile neutropenia: management and prevention. Clinical Medicine. 8(4). 448–451. 1 indexed citations

Carino, Nicola de Liguori, et al.. (2008). Extensive necrosis of visceral melanoma metastases after immunotherapy. World Journal of Surgical Oncology. 6(1). 30–30. 9 indexed citations

Innes, Helen, et al.. (2007). Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Supportive Care in Cancer. 16(5). 485–491. 58 indexed citations

10.

O'Neill, P A, et al.. (2001). A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer. Oncology. 61(Suppl. 1). 25–29. 12 indexed citations

11.

Marshall, Ernest, et al.. (2000). Ten-year survival in advanced malignant melanoma following treatment with interferon and vindesine. Annals of Oncology. 11(4). 483–486. 8 indexed citations

12.

Marshall, Ernest, et al.. (2000). Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients. Supportive Care in Cancer. 8(3). 198–202. 10 indexed citations

13.

Marshall, Ernest, Anthony Howell, R Powles, et al.. (1998). Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1α (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010. European Journal of Cancer. 34(7). 1023–1029. 13 indexed citations

14.

Meyers, Frederick J., Danika L. Lew, Primo N. Lara, et al.. (1998). Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124). Investigational New Drugs. 16(4). 347–351. 3 indexed citations

15.

Marshall, Ernest, et al.. (1997). Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide. British Journal of Cancer. 75(12). 1715–1720. 18 indexed citations

16.

Lord, B. I., et al.. (1996). BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation. British Journal of Cancer. 74(7). 1017–1022. 17 indexed citations

17.

Marshall, Ernest & B. I. Lord. (1996). Feedback Inhibitors in Normal and Tumor Tissues. International review of cytology. 167. 185–261. 8 indexed citations

18.

Marshall, Ernest. (1995). Haemopoietic stem cell inhibition: Potential for dose intensification. European Journal of Cancer. 31(10). 1586–1591. 2 indexed citations

19.

Wolf, Michael, et al.. (1994). Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.. Journal of Clinical Oncology. 12(9). 1868–1875. 123 indexed citations

20.

Francis, Brian R., Jean H. Overmeyer, William J. John, Ernest Marshall, & Boyd E. Haley. (1989). Prevalence of nucleoside diphosphate kinase autophosphorylation in human colon carcinoma versus normal colon homogenates. Molecular Carcinogenesis. 2(3). 168–178. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact